Minakem Generic APIs Minakem Generic APIs

X
[{"orgOrder":0,"company":"Venture Life","sponsor":"Jaguar Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Jaguar Health Licenses FDA-approved Oral Mucositis Product for U.S. Market, Initiating Commercial Footprint in its Core Focus Area of Cancer Supportive Care","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"April 2024","url1":"","url2":"","graph1":"Immunology","graph2":"Approved"}]

Find Clinical Drug Pipeline Developments & Deals by Venture Life

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Under the license agreement, Jaguar Health will commercialize Gelclair in the U.S. market. It is indicated to alleviate pain by adhering to the mucosal surface of the mouth and treating oral lesions, including oral mucositis/stomatitis.

            Lead Product(s): Maltodextrin

            Therapeutic Area: Immunology Product Name: Gelclair

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Jaguar Health

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement April 16, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY